Investigational drug · Phase 2
CTX-712
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukemia, Myelodysplastic Syndromes.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CTX-712"
First trial start
2023
Apr 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CTX-712", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "CTX-712" as an intervention, largest first.
Chordia Therapeutics, Inc.Industry
NCT05732103 · 225 participants (planned) · Start Apr 25, 2023 · Primary completion Jun 2028
Drug: CTX-712 · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes
Sites: Phoenix, Arizona; Jacksonville, Florida; Chicago, Illinois · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.
Sato J, Katsuya Y, Koyama T, et al. · Clin Cancer Res 2026
- Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.
Yokoyama H, Fukuhara N, Ando K, et al. · Blood Adv 2026
- Discovery of Rogocekib (CTX-712): A Potent and Selective CLK Inhibitor for Cancer Treatment.
Kawakita Y, Kojima T, Nii N, et al. · ACS Med Chem Lett 2025
Also in development for Acute Myeloid Leukemia
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- GM-CSFPhase 32 trials
Y-mAbs Therapeutics · Neuroblastoma, Acute Myeloid Leukemia
- HMPL-306Phase 32 trials
Hutchmed · Acute Myeloid Leukemia, Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RVU120SEL120Phase 23 trials
Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- IMGN632Phase 22 trials
AbbVie · Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.